Activation of the PI3K/Akt/mTOR signaling axis has been implicated in therapeutic resistance and metabolic reprogramming of many tumor types in response to both chemotherapy and targeted therapies [279] (Figure 3). Here, PIK3CA is linked to neoplasm.